PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1100101
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1100101
The Asia-Pacific medication-assisted treatment (MAT) market is projected to register a substantial CAGR of 10.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Asia-Pacific Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific) Industry Trends and Forecast to 2029
The rise in incidence of alcohol use disorder and opioid use disorders
Increasing awareness of MAT
Indivior PLC
Sun Pharmaceutical Industries Ltd.
Taj Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Pfizer Inc.
Glenmark Pharmaceutical Inc.
Viatris Inc.
Alvogen
Accord Healthcare
Teva Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Ltd.
Amneal Pharmaceuticals LLC. among others